Wednesday, July 8, 2026

biotech · Choroideremia · X-Linked Retinitis Pigmentosa · FDMT

4D Molecular Therapeutics

4D Molecular Therapeutics patent portfolio — 15 USPTO pharmaceutical patents (A61K/A61P) with grant dates, status, and loss-of-exclusivity filters.

5858 Horton St, 455, Emeryville, California 94608, US HQ
2013 Founded
213 Employees
Public company Type
FDMT · NYSE Ticker
Company details
Status
Public
HQ
5858 Horton St, 455, Emeryville, California 94608, US
Founded
2013
Employees
213
Programs
19
Drugs
13
Patents
15
Intelligence · Patents

4D Molecular Therapeutics patents

15 pharmaceutical patents indexed for 4D Molecular Therapeutics. 0 expire within 24 months.

4D Molecular Therapeutics has 15 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 0 expire within 24 months — use filters for patent-cliff planning.

Patent portfolio

  1. US 11840704

    Adeno-associated virus variant capsids and methods of use thereof

    Expires Mon Dec 07 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  2. US 11807868

    Adeno-associated variants, formulations and methods for pulmonary delivery

    Expires Mon Nov 02 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  3. US 11766489

    Adeno-associated virus variant capsids and use for inhibiting angiogenesis

    Expires Mon Sep 21 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  4. US 11766487

    Treatments for retinal disease

    Expires Mon Sep 21 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  5. US 11576983

    Treatments for retinal disease

    Expires Mon Feb 09 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  6. US 11524081

    Codon optimized REP1 genes and uses thereof

    Expires Mon Dec 08 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  7. US 11499166

    Adeno-associated variants, formulations and methods for pulmonary delivery

    Expires Mon Nov 10 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  8. US 11419949

    Adeno-associated virus variant capsids and methods of use thereof

    Expires Mon Aug 18 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  9. US 11364308

    Adeno-associated virus variant capsids and methods of use thereof

    Expires Mon Jun 16 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  10. US 11357870

    Codon optimized REP1 genes and uses thereof

    Expires Mon Jun 09 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  11. US 11345930

    Codon optimized RPGRORF15 genes and uses thereof

    Expires Mon May 26 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  12. US 11198858

    Codon optimized GLA genes and uses thereof

    Expires Mon Dec 09 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  13. US 11179477

    Method of using adeno-associated virus with variant capsid

    Expires Mon Nov 18 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  14. US 11167041

    Adeno-associated virus variant capsids and methods of use thereof

    Expires Mon Nov 04 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  15. US 11118192

    Adeno-associated virus variant capsids and methods of use thereof

    Expires Mon Sep 09 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

How many patents does 4D Molecular Therapeutics have?

15 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).

When do 4D Molecular Therapeutics patents expire?

0 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.